Sugi Predict

Sugi Predict / Compounds / SCHEMBL1933892

SCHEMBL1933892

SCHEMBL1933892

Nc1ncnc2c1c(I)cn2C1CCC(=O)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MTOR P42345 1/20 0.52
▸ RAB9A P51151 1/20 0.52
▸ ADK P55263 9/20 0.51
▸ SRC P12931 5/20 0.49
▸ ABL1 P00519 5/20 0.49
▸ DAPK3 O43293 1/20 0.49
▸ MAP4K4 O95819 1/20 0.49
▸ PAK4 O96013 1/20 0.49
▸ LCK P06239 1/20 0.49
▸ FYN P06241 1/20 0.49
▸ CSF1R P07333 1/20 0.49
▸ RET P07949 1/20 0.49
▸ IGF1R P08069 1/20 0.49
▸ FGFR1 P11362 1/20 0.49
▸ PRKACA P17612 1/20 0.49
▸ FLT1 P17948 1/20 0.49
▸ LTK P29376 1/20 0.49
▸ KDR P35968 1/20 0.49
▸ MAP2K2 P36507 1/20 0.49
▸ FLT3 P36888 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16237288 0.89 SRC (0.59) MTORRAB9AADKSRCABL1
SCHEMBL1441949 0.86 MTOR (0.52) MTORRAB9AADKSRCABL1
SCHEMBL1441902 0.86 MTOR (0.57) MTORRAB9AADKSRCABL1
SCHEMBL29484468 0.86 SRC (0.61) MTORRAB9AADKSRCABL1
SCHEMBL30155310 0.86 ABL1 (0.64) MTORRAB9AADKSRCABL1
SCHEMBL400626 0.86 SRC (0.61) MTORRAB9AADKSRCABL1
SCHEMBL1940882 0.86 ABL1 (0.64) MTORRAB9AADKSRCABL1
SCHEMBL17818397 0.85 ABL1 (0.63) MTORRAB9AADKSRCABL1
SCHEMBL3819981 0.84 ADK (0.48) MTORRAB9AADKSRCABL1
SCHEMBL1933264 0.83 RIPK2 (0.63) MTORRAB9AADKSRCABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115298180-B Compounds for treating or inhibiting recurrence of acute myeloid leukemia 日本理化学研究所 2025-06-10 — — CN disclosed
EP-3795571-B1 ALKYNYL(HETERO)AROMATIC COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY SHENZHEN TARGETRX INC (CN) 2024-05-08 — — EP disclosed
US-11963960-B2 Compounds for treating or inhibiting recurrence of acute myeloid leukemia FLASH THERAPEUTICS, LLC (US) 2024-04-23 — — US disclosed
US-11840535-B2 Alkynyl(hetero)aromatic compound for inhibiting protein kinase activity SHENZHEN TARGETRX, INC. (CN) 2023-12-12 — — US disclosed
US-11840535-B2 Alkynyl(hetero)aromatic compound for inhibiting protein kinase activity SHENZHEN TARGETRX, INC. (CN) 2023-12-12 — — US disclosed
US-11840535-B2 Alkynyl(hetero)aromatic compound for inhibiting protein kinase activity SHENZHEN TARGETRX, INC. (CN) 2023-12-12 — — US disclosed
EP-4121430-A1 COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA Flash Therapeuttics, LLC (US) 2023-01-25 — — EP disclosed
CN-115298180-A Compounds for treating or inhibiting recurrence of acute myeloid leukemia 富雷旭医疗有限责任公司 2022-11-04 — — CN disclosed
CN-110194772-B Alkynyl (hetero) aromatic ring compounds for inhibiting protein kinase activity 深圳市塔吉瑞生物医药有限公司 2022-04-05 — — CN disclosed
US-20210299128-A1 COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA RIKEN (JP) 2021-09-30 — — US disclosed
EP-1973917-B1 PROTEIN KINASE INHIBITORS ABBVIE INC (US) 2015-06-10 — — EP disclosed
EP-2878601-A1 AGENT FOR TREATING OR CONTROLLING RECURRENCE OF ACUTE MYELOGENOUS LEUKEMIA Riken (JP) 2015-06-03 — — EP disclosed
US-20120289501-A1 Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls NOVARTIS AG (CH) 2012-11-15 — — US disclosed
EP-2504339-A1 BENZENE-FUSED 6-MEMBERED OXYGEN-CONTAINING HETEROCYCLIC DERIVATIVES OF BICYCLIC HETEROARYLS Novartis AG (CH) 2012-10-03 — — EP disclosed
WO-2011064211-A1 BENZENE-FUSED 6-MEMBERED OXYGEN-CONTAINING HETEROCYCLIC DERIVATIVES OF BICYCLIC HETEROARYLS NOVARTIS AG (CH) 2011-06-03 — — WO disclosed
US-7772231-B2 Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors ABBOTT LABORATORIES (US) 2010-08-10 — — US disclosed
EP-1973917-A2 PROTEIN KINASE INHIBITORS Abbott Laboratories (US) 2008-10-01 — — EP disclosed
US-20070203143-A1 PROTEIN KINASE INHIBITORS ABBVIE INC. 2007-08-30 — — US disclosed
WO-2007079164-A2 PROTEIN KINASE INHIBITORS ABBOTT LABORATORIES (US) 2007-07-12 — — WO disclosed
US-20060025383-A1 Aminobenzoxazoles as therapeutic agents ABBOTT LABORATORIES 2006-02-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289501-A1 Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls CYP1B1, CYP11B2, CCNI MTOR 926/4885RAB9A 3325/4885ADK 3863/4885
US-20060025383-A1 Aminobenzoxazoles as therapeutic agents ABL1, MAP3K19, MAP3K20 MTOR 39/4885RAB9A 2517/4885ADK 144/4885
US-11963960-B2 Compounds for treating or inhibiting recurrence of acute myeloid leukemia MCL1, FLT3, ABL1 MTOR 855/4885RAB9A 2888/4885ADK 268/4885
US-20210299128-A1 COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA MCL1, FLT3, ABL1 MTOR 855/4885RAB9A 2888/4885ADK 268/4885
US-11840535-B2 Alkynyl(hetero)aromatic compound for inhibiting protein kinase activity ALK, BRAF, DSTYK MTOR 221/4885RAB9A 945/4885ADK 272/4885
US-20070203143-A1 PROTEIN KINASE INHIBITORS PACSIN2, MAP3K20, PHKG1 MTOR 121/4885RAB9A 1753/4885ADK 249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.